Intarcia Therapeutics

Biotech & Life Sciences · Boston, United States · Founded 1997

Intarcia Therapeutics is a pioneering company focused on redesigning the treatment of chronic diseases through innovative therapies that integrate medicine with technology. Operating in the biopharmaceutical sector, Intarcia serves patients suffering from chronic conditions, aiming to improve their quality of life with advanced drug delivery systems. The company's core product is the Medici Drug Delivery System, an investigational technology designed to provide consistent and long-term delivery of medication. Intarcia's business model revolves around the development and commercialization of these cutting-edge therapies, generating revenue through partnerships, licensing agreements, and direct sales. By placing patients at the center of their mission, Intarcia is committed to transforming therapeutic categories and setting new standards in chronic disease management. Keywords: chronic disease, innovative therapies, drug delivery, biopharmaceutical, Medici System, technology integration, patient-centric, commercialization, partnerships, licensing.

Valuation $2.5–5B

Revenue <$1M

Headcount <100

Total funding $1–2.5B

Unlock exact values

Power Law Unicorn$1–10B valuation tier

Investors

10 investors on Intarcia Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 10 investors entered at this stage

Alta Partners

Marker LLC

RA Capital Management

Farallon Capital Management

Baillie Gifford

Bill & Melinda Gates Foundation

Global footprint

Where Intarcia Therapeutics has talent and traffic

Workforce by country

4 countries with
team presence

🇺🇸 United States93.5%

🇵🇰 Pakistan2.2%

🇮🇪 Ireland2.2%

🇮🇳 India2.2%

4 countries shown

Web traffic by country

930 monthly visits
across markets

🇺🇸 United States96.8%

Top 1 markets shown

Talent graph

The shape of Intarcia Therapeutics's talent

Dealroom maps Intarcia Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

32 team members profilednamed & role-tagged by Dealroom

69 employeestotal headcount

2 executives & foundersidentified by name

DimensionScore

AI Talent

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Intarcia Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$49M patent portfolio · 21 active families

Estimated portfolio value

$49M

1.3% of valuation · comparable to top peer Camurus ($49M)

21 active patent families

Where Intarcia Therapeutics innovates Active agentBiomedical engineeringDelivery systemDiseaseDrug delivery

Where Intarcia Therapeutics concentrates vs peers

Each axis is a top-10 topic across Intarcia Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Intarcia Therapeutics

An AI-synthesized read of the highest-engagement posts about Intarcia Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Intarcia Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles